Neumora Therapeutics stock hits 52-week low at $1.11

In a challenging turn for Neumora Therapeutics, the biotech company’s stock has plummeted to a 52-week low, trading at $1.11. According to InvestingPro data, while the company maintains a strong current ratio of 10.51 and holds more cash than debt, it’s quickly burning through available resources. This latest price point underscores a significant downturn for the company, which has experienced a staggering 1-year change with its stock value eroding by -91.04%. Investors have been closely monitoring Neumora’s performance, as the stock’s downward trajectory reflects broader concerns in the biotech sector, where volatility is often driven by clinical trial outcomes and regulatory hurdles. InvestingPro analysis suggests the stock is currently undervalued, though analysts project continued losses this year. The 52-week low serves as a critical indicator of the company’s current market position and investor sentiment. For deeper insights into Neumora’s financial health and growth prospects, including 13 additional ProTips and comprehensive analysis, check out the full research report on InvestingPro.

In other recent news, Neumora Therapeutics reported its fourth-quarter financial results, surpassing earnings expectations with an adjusted loss per share of -$0.37 against analyst estimates of -$0.62. Despite this positive financial performance, the company announced a temporary pause and optimization of its KOASTAL-2 and KOASTAL-3 clinical trials for navacaprant, with plans to resume in March 2025. The adjustments follow the KOASTAL-1 study’s failure to meet its primary endpoint, prompting changes such as enhanced medical monitoring and a reduction in clinical sites. Neumora also decided to discontinue its Phase II trial in bipolar depression to concentrate resources on the KOASTAL program.

Analysts have responded to these developments with mixed ratings. William Blair downgraded Neumora from Outperform to Market Perform, citing lowered confidence in the kappa opioid receptor antagonist mechanism after Johnson & Johnson discontinued its similar aticaprant program. Conversely, H.C. Wainwright reaffirmed a Buy rating with an $18.00 target, expressing confidence in navacaprant’s potential despite the industry setbacks. Stifel analysts downgraded Neumora to Hold, reducing their price target from $6.00 to $2.00, while Guggenheim maintained a Buy rating with a $7.00 target, highlighting the company’s strategic adjustments. Neumora holds $307.6 million in cash, expected to fund operations into mid-2026, as it continues to advance its clinical trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.